ABSTRACT
Atrioventricular node (AVN) ablation is a strategy to manage patients with drug-refractory atrial fibrillation (AF) and heart failure in whom cardiac resynchronization therapy (CRT) device implantation has been prescribed. This study describes a practical method to perform these two procedures using the same surgical site. Twenty-seven patients were indicated for AVN ablation and concurrent CRT device implantation while presenting with AF and rapid ventricular response (RVR) refractory to medical therapy. After placement of the right and left ventricular leads, a third puncture was made in the axillary vein to obtain access to perform the ablation. After hand-injecting contrast media through a RAMP™ (Abbott Laboratories, Chicago, IL, USA) sheath positioned in the right atrial cavity, the anatomical area corresponding to the AVN was identified using fluoroscopy cine runs obtained in the right anterior oblique and left anterior oblique projections. The adequate site for ablation was confirmed by the bipolar recording of a His-bundle deflection at the tip of the ablation catheter. Radiofrequency energy was delivered to achieve complete heart block. Subsequently, device implant was completed. The method was successfully applied in 27 consecutive cases, achieving permanent complete heart block in all patients. The mean radiofrequency time to achieve heart block was 110 seconds ± 43 seconds. The average procedural time including AVN ablation and device implant was 87 minutes ± 21 minutes. The images obtained with the hand-injected contrast media provided adequate information to readily identify the anatomical area corresponding to the AVN with 100% accuracy. This study suggests that ablation of the AVN can be safely and effectively accomplished via a superior approach in patients undergoing a CRT device implant.
ABSTRACT
AIMS: Right ventricular (RV) pacing has been shown to be potentially detrimental to left ventricular function. In conventional dual-chamber pacing the position of the atrial lead could influence duration of the atrio-ventricular (AV) intervals, which is one of the variables that could be associated with an increased percentage of RV pacing. We wanted to see if lead placement at selected atrial septal sites could reduce AV intervals in patients receiving a dual-chamber pacemaker or implantable cardioverter defibrillator. METHODS AND RESULTS: This was a prospective, acute, randomized single centre study that enrolled 57 patients. The atrial lead was placed in both the right atrial appendage (RAA) and the lower atrial septum (LAS) in each patient in random order. The P-wave durations, PR intervals, A sense-V sense (As-Vs), and A pace-V sense (Ap-Vs) intervals were measured at both atrial lead locations in each patient during device implant. The P-wave durations during sinus rhythm (SR), RAA pacing, and LAS pacing were 113 ± 19, 144 ± 27, and 84 ± 12 ms (RAA vs. LAS, P < 0.001), respectively. The PR intervals during SR, RAA pacing, and LAS pacing were 195 ± 47, 230 ± 61, and 167 ± 44 ms (RAA vs. LAS, P < 0.001), respectively. The As-Vs interval was 31% shorter in LAS pacing than in RAA pacing (134 ± 44 ms vs. 194 ± 52 ms, P < 0.001). The Ap-Vs interval was 24% shorter during LAS pacing than during RAA pacing (195 ± 45 ms vs. 257 ± 63 ms, P < 0.001). CONCLUSION: When compared with RAA pacing, LAS pacing was associated with a shorter P wave duration, PR interval, As-Vs, and Ap-Vs intervals. The potential long-term impact of the strategy of pacing from LAS in reducing unnecessary RV pacing needs to be explored in future studies.
